Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 16/20 | 1.00 |
| ▸ | S1PR1 | P21453 | 10/20 | 0.82 |
| ▸ | S1PR3 | Q99500 | 7/20 | 0.82 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13271335 | 1.00 | S1PR5 (1.00) | S1PR5S1PR1S1PR3S1PR4MEN1 | |
| SCHEMBL3036736 | 1.00 | S1PR5 (1.00) | S1PR5S1PR1S1PR3S1PR4MEN1 | |
| SCHEMBL3039328 | 0.93 | S1PR5 (1.00) | S1PR5S1PR1S1PR3S1PR4ALDH1A1 | |
| SCHEMBL3039326 | 0.93 | S1PR5 (1.00) | S1PR5S1PR1S1PR3S1PR4ALDH1A1 | |
| SCHEMBL3041648 | 0.93 | S1PR5 (1.00) | S1PR5S1PR1S1PR3S1PR4ALDH1A1 | |
| SCHEMBL3041709 | 0.93 | S1PR5 (1.00) | S1PR5S1PR1S1PR3S1PR4MEN1 | |
| SCHEMBL3043580 | 0.90 | S1PR5 (1.00) | S1PR5S1PR1S1PR3S1PR4 | |
| SCHEMBL3043562 | 0.89 | S1PR5 (1.00) | S1PR5S1PR1S1PR3S1PR4 | |
| SCHEMBL13259647 | 0.88 | S1PR5 (0.78) | S1PR5S1PR1S1PR3S1PR4MEN1 | |
| SCHEMBL3031896 | 0.86 | S1PR5 (0.95) | S1PR5S1PR1S1PR3S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216762-A1 | Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2010-08-26 | — | — | US | claimed |
| US-20100216762-A1 | Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100216762-A1 | Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100216762-A1 | Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216762-A1 | Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof | S1PR5, LPAR5, S1PR1 | S1PR5 1/4885S1PR1 3/4885S1PR3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.